Literature DB >> 30659283

Prognostic factors for one-year mortality in patients with acute heart failure with and without chronic kidney disease: differential impact of beta-blocker and diuretic treatments.

Kenichi Matsushita1, Toshinori Minamishima2, Konomi Sakata2, Toru Satoh2, Hideaki Yoshino2.   

Abstract

The pathophysiology and treatment of acute decompensated heart failure (HF) in the presence of chronic kidney disease (CKD) remain ill defined. Here we compared the prognostic factors for 1-year mortality in patients with acute HF with and without CKD. We retrospectively studied 392 consecutive patients with acute decompensated HF. CKD as a comorbidity in these patients was defined by an estimated glomerular filtration rate of <60 mL/min/1.73 m2. Potential risk factors for 1-year mortality were selected by univariate analyses; then multivariate Cox regression analysis with forward selection (likelihood ratio) was performed to identify significant factors. Across the study cohort, 65% of patients had CKD, and the 1-year mortality rate was 9.2%. In the HF with CKD group, older age, lower systolic blood pressure at admission, discharge medications without beta-blockers, and discharge medications without diuretics were independent risk factors for 1-year mortality. In contrast, coexisting chronic obstructive pulmonary disease and higher C-reactive protein levels were independent risk factors for 1-year mortality in the HF without CKD group. Kaplan-Meier survival curves showed that discharge medications with no beta-blockers or diuretics correlated with significantly lower survival rates in patients with CKD (P < 0.001 in both groups, log-rank test), but not in patients without CKD (P = 0.822 and P = 0.374, respectively, log-rank test). Thus, there were significant differences in the prognostic factors for 1-year mortality between acute HF patients with and without CKD including beta-blocker and diuretic treatments. These findings suggest that patients with HF might benefit from individualized therapies.

Entities:  

Keywords:  cardiorenal syndrome; chronic kidney disease; heart failure; individualized treatment

Mesh:

Substances:

Year:  2019        PMID: 30659283     DOI: 10.1038/s41440-018-0204-4

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  2 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  Effects of carvedilol and BL-443 on kidney of rats with cyclosporine nephropathy.

Authors:  J Salplachta; L Bartosíková; J Necas
Journal:  Gen Physiol Biophys       Date:  2002-06       Impact factor: 1.512

  2 in total
  2 in total

Review 1.  Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice.

Authors:  Pupalan Iyngkaran; Merlin Thomas; John D Horowitz; Paul Komesaroff; Michael Jelinek; David L Hare
Journal:  Curr Cardiol Rev       Date:  2021

2.  Effect of Hypertonic Saline Solution Combined with Furosemide on Acute Heart Failure: A Meta-Analysis.

Authors:  Zuoqing Li; ZuanJin Wang; Nanchao Liu; Haili Li
Journal:  Comput Math Methods Med       Date:  2022-09-21       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.